Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors

Kazuto Furuyama, Taishi Harada, Eiji Iwama, Yoshimasa Shiraishi, Kyoko Okamura, Kayo Ijichi, Akiko Fujii, keiichi ota, Shuo Wang, Heyan Li, Koichi Takayama, Giuseppe Giaccone, Yoichi Nakanishi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The presence of epidermal growth factor receptor (EGFR) somatic mutations in non-small-cell lung cancer patients is associated with response to treatment with EGFR-tyrosine kinase inhibitors, such as gefitinib and erlotinib. More than 100 mutations in the kinase domain of EGFR have been identified. In particular there are many variations of deletion mutations in exon 19. In this study, using yellow fluorescent protein-tagged fragments of the EGFR intracellular domain, we examined the differences in sensitivity to gefitinib, erlotinib and afatinib between several exon 19 mutants and other common EGFR mutations. We also used serum of patients undergoing treatment with EGFR-tyrosine kinase inhibitors in this system. In addition, we examined the relative kinase activity of these mutants by measuring relative fluorescent intensity after immunofluorescence staining. We found that both sensitivity to EGFR-tyrosine kinase inhibitors and relative kinase activity differed among several EGFR mutations found in the same region of the kinase domain. This study underscores the importance of reporting the clinical outcome of treatment in relation to different EGFR mutations.

Original languageEnglish
Pages (from-to)584-589
Number of pages6
JournalCancer Science
Volume104
Issue number5
DOIs
Publication statusPublished - May 1 2013

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Exons
Mutation
Phosphotransferases
Sequence Deletion
Non-Small Cell Lung Carcinoma
Fluorescent Antibody Technique
Staining and Labeling
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. / Furuyama, Kazuto; Harada, Taishi; Iwama, Eiji; Shiraishi, Yoshimasa; Okamura, Kyoko; Ijichi, Kayo; Fujii, Akiko; ota, keiichi; Wang, Shuo; Li, Heyan; Takayama, Koichi; Giaccone, Giuseppe; Nakanishi, Yoichi.

In: Cancer Science, Vol. 104, No. 5, 01.05.2013, p. 584-589.

Research output: Contribution to journalArticle

Furuyama, K, Harada, T, Iwama, E, Shiraishi, Y, Okamura, K, Ijichi, K, Fujii, A, ota, K, Wang, S, Li, H, Takayama, K, Giaccone, G & Nakanishi, Y 2013, 'Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors', Cancer Science, vol. 104, no. 5, pp. 584-589. https://doi.org/10.1111/cas.12125
Furuyama, Kazuto ; Harada, Taishi ; Iwama, Eiji ; Shiraishi, Yoshimasa ; Okamura, Kyoko ; Ijichi, Kayo ; Fujii, Akiko ; ota, keiichi ; Wang, Shuo ; Li, Heyan ; Takayama, Koichi ; Giaccone, Giuseppe ; Nakanishi, Yoichi. / Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. In: Cancer Science. 2013 ; Vol. 104, No. 5. pp. 584-589.
@article{9c03808d4f954f468cf4044ef4847678,
title = "Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors",
abstract = "The presence of epidermal growth factor receptor (EGFR) somatic mutations in non-small-cell lung cancer patients is associated with response to treatment with EGFR-tyrosine kinase inhibitors, such as gefitinib and erlotinib. More than 100 mutations in the kinase domain of EGFR have been identified. In particular there are many variations of deletion mutations in exon 19. In this study, using yellow fluorescent protein-tagged fragments of the EGFR intracellular domain, we examined the differences in sensitivity to gefitinib, erlotinib and afatinib between several exon 19 mutants and other common EGFR mutations. We also used serum of patients undergoing treatment with EGFR-tyrosine kinase inhibitors in this system. In addition, we examined the relative kinase activity of these mutants by measuring relative fluorescent intensity after immunofluorescence staining. We found that both sensitivity to EGFR-tyrosine kinase inhibitors and relative kinase activity differed among several EGFR mutations found in the same region of the kinase domain. This study underscores the importance of reporting the clinical outcome of treatment in relation to different EGFR mutations.",
author = "Kazuto Furuyama and Taishi Harada and Eiji Iwama and Yoshimasa Shiraishi and Kyoko Okamura and Kayo Ijichi and Akiko Fujii and keiichi ota and Shuo Wang and Heyan Li and Koichi Takayama and Giuseppe Giaccone and Yoichi Nakanishi",
year = "2013",
month = "5",
day = "1",
doi = "10.1111/cas.12125",
language = "English",
volume = "104",
pages = "584--589",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors

AU - Furuyama, Kazuto

AU - Harada, Taishi

AU - Iwama, Eiji

AU - Shiraishi, Yoshimasa

AU - Okamura, Kyoko

AU - Ijichi, Kayo

AU - Fujii, Akiko

AU - ota, keiichi

AU - Wang, Shuo

AU - Li, Heyan

AU - Takayama, Koichi

AU - Giaccone, Giuseppe

AU - Nakanishi, Yoichi

PY - 2013/5/1

Y1 - 2013/5/1

N2 - The presence of epidermal growth factor receptor (EGFR) somatic mutations in non-small-cell lung cancer patients is associated with response to treatment with EGFR-tyrosine kinase inhibitors, such as gefitinib and erlotinib. More than 100 mutations in the kinase domain of EGFR have been identified. In particular there are many variations of deletion mutations in exon 19. In this study, using yellow fluorescent protein-tagged fragments of the EGFR intracellular domain, we examined the differences in sensitivity to gefitinib, erlotinib and afatinib between several exon 19 mutants and other common EGFR mutations. We also used serum of patients undergoing treatment with EGFR-tyrosine kinase inhibitors in this system. In addition, we examined the relative kinase activity of these mutants by measuring relative fluorescent intensity after immunofluorescence staining. We found that both sensitivity to EGFR-tyrosine kinase inhibitors and relative kinase activity differed among several EGFR mutations found in the same region of the kinase domain. This study underscores the importance of reporting the clinical outcome of treatment in relation to different EGFR mutations.

AB - The presence of epidermal growth factor receptor (EGFR) somatic mutations in non-small-cell lung cancer patients is associated with response to treatment with EGFR-tyrosine kinase inhibitors, such as gefitinib and erlotinib. More than 100 mutations in the kinase domain of EGFR have been identified. In particular there are many variations of deletion mutations in exon 19. In this study, using yellow fluorescent protein-tagged fragments of the EGFR intracellular domain, we examined the differences in sensitivity to gefitinib, erlotinib and afatinib between several exon 19 mutants and other common EGFR mutations. We also used serum of patients undergoing treatment with EGFR-tyrosine kinase inhibitors in this system. In addition, we examined the relative kinase activity of these mutants by measuring relative fluorescent intensity after immunofluorescence staining. We found that both sensitivity to EGFR-tyrosine kinase inhibitors and relative kinase activity differed among several EGFR mutations found in the same region of the kinase domain. This study underscores the importance of reporting the clinical outcome of treatment in relation to different EGFR mutations.

UR - http://www.scopus.com/inward/record.url?scp=84876416258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876416258&partnerID=8YFLogxK

U2 - 10.1111/cas.12125

DO - 10.1111/cas.12125

M3 - Article

C2 - 23387505

AN - SCOPUS:84876416258

VL - 104

SP - 584

EP - 589

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -